Subcutaneous injection · 20 mcg/day for 10 days · 1–2 courses per year
Half-life
Short — tripeptide; effects via gene regulatory interactions in mucosal epithelial tissue
Most studied use
Respiratory mucosal health · Gut barrier integrity · Gut-lung axis support · Mucosal aging prevention
Regulatory status
Not FDA-approved · Research chemical · Used in Russian clinical practice
Human evidence
Limited — small Russian clinical studies in chronic bronchitis patients. Gut human data is sparse.
Preclinical evidence
Moderate — mucosal epithelial proliferation, tight junction upregulation, protection against mucosal injury in both bronchial and intestinal models
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
What is Chonluten?
Chonluten is a synthetic tripeptide — Gly-Glu-Pro (GEP) — developed by Professor Vladimir Khavinson as the mucosal bioregulator. It is a Cytogen: the injectable synthetic short-peptide form. Its tissue target is mucosal epithelium — the specialized lining that covers both the airways and the gut — making it unique in the bioregulator series for having a dual organ focus.
The gut-lung axis is not a fringe concept — it is a well-established bidirectional relationship in contemporary immunology. The microbiome communicates with the respiratory immune system; gut barrier integrity influences pulmonary inflammation; post-infectious gut changes affect respiratory outcomes. Khavinson's identification of a peptide that acts on both mucosal systems predated widespread Western awareness of this axis.
The GEP tripeptide is one of the simplest in the Cytogen series — three amino acids (glycine-glutamic acid-proline). Its small size may contribute to good tissue penetration across mucosal surfaces, though this is not formally established.
How it works
Mucosal Epithelial Chromatin Interaction
Consistent with the Khavinson model, Chonluten is proposed to interact with chromatin in mucosal epithelial cells — regulating gene expression in both bronchial and intestinal mucosal tissue. The same peptide sequence appearing to work in two tissue types is explained by the structural and embryological similarity between lung and gut epithelium (both derived from endoderm) and their shared gene expression programs.
Mucosal Barrier Reinforcement
Cell studies show Chonluten upregulates tight junction protein expression in epithelial cells — the proteins responsible for sealing the mucosal barrier and preventing inappropriate passage of antigens and microorganisms. This barrier function is critical in both the gut (preventing “leaky gut” phenotypes) and the lungs (preventing pathogen entry into lung tissue).
Anti-Inflammatory Mucosal Signaling
Research shows Chonluten modulates mucosal inflammatory cytokine production — reducing pathological inflammation while preserving immune surveillance. This targeted anti-inflammatory effect at the mucosal interface is distinct from systemic anti-inflammatory approaches and avoids the immunosuppressive risk of broader interventions.
What the research shows
NOTE — PRIMARILY KHAVINSON GROUP DATA · LUNG DATA STRONGER THAN GUT DATA · NO WESTERN RCTS
STUDYBulletin of Experimental Biology and Medicine · 2006
Chonluten in Chronic Bronchitis — Mucosal Outcomes
Khavinson VK et al.
Patients with chronic bronchitis receiving Chonluten showed improved mucociliary clearance, reduced exacerbation frequency, and improved spirometry parameters vs. controls at 6-month follow-up. Bronchial epithelial biopsy showed reduced inflammatory changes in the treatment group.
STUDYJournal of Bioregulatory and Homeostatic Agents · 2008
GEP Tripeptide Effects on Intestinal Epithelial Barrier Integrity
Khavinson VK et al.
Chonluten (GEP) promoted intestinal epithelial cell proliferation and tight junction integrity in culture models of mucosal injury. Protection against chemically induced mucosal damage was observed in animal intestinal models, providing mechanistic support for gut application.
Dual Organ Activity: GEP Uptake and Gene Expression in Bronchial and Intestinal Tissue
Khavinson VK et al.
The GEP tripeptide showed uptake and transcriptional activity in both bronchial and intestinal epithelial tissue in the same animal subjects — providing mechanistic support for the dual organ targeting. Gene expression changes in both tissue types were consistent with epithelial repair programs.
Chonluten has low biohacker popularity relative to the thymic and pineal bioregulators — it occupies a specialized niche for people with gut-lung health concerns: inflammatory bowel conditions, chronic respiratory disease, post-infectious mucosal damage, or people focused on gut barrier integrity. It is rarely a first-choice compound in general longevity protocols.
Anecdotal reports cluster around improved gut tolerance, reduced bloating, and improved respiratory symptoms in people using it for mucosal repair. The gut-lung axis framing resonates strongly with the growing longevity community interest in gut health — but the evidence base is narrower than the interest suggests.
WHAT THE RESEARCH SHOWS
✓KNOWN
✓Chonluten (GEP) targets both lung and gut mucosal epithelium — the only dual-organ Cytogen in the bioregulator series
✓Cell studies show tight junction upregulation and epithelial barrier reinforcement in both tissue types
✓Animal studies show protection against mucosal injury in both bronchial and intestinal models
✓Small human clinical data shows spirometry and bronchial mucosal improvement in chronic bronchitis as adjunct therapy
✓GEP tripeptide activity in two tissue types is supported by their embryological similarity (both endoderm-derived)
?UNCERTAIN
?Whether Chonluten produces measurable benefit in people without existing mucosal pathology (healthy prevention)
?Human gut mucosal data is sparse — most clinical evidence is bronchial. Gut benefit is mechanistically supported but less clinically characterized.
?Optimal dosing — protocols are extrapolated from the broader Khavinson framework rather than Chonluten-specific dose-finding studies
?Whether gut-lung axis benefits are mechanistically proven or inferred from dual-tissue activity data
?Independent Western-standard replication of either lung or gut mucosal effects in controlled trials
RECONSTITUTION CALCULATOR
EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN
AI COACH PREVIEW
I have mild IBS and some respiratory sensitivity. I'm interested in Chonluten for the gut-lung angle. How would I integrate it and what should I realistically expect?
Chonluten is a reasonable choice here, but expectations management is important. The gut-lung axis effect is mechanistically supported but clinically characterized primarily on the bronchial side — the gut human data is thinner. That said, for someone with both gut and respiratory sensitivity, targeting mucosal epithelium from both angles makes sense. The protocol: 20 mcg/day SC for 10 days, 1–2 courses per year. I'd start with one course and track both gut symptoms and respiratory sensitivity over 3 months before deciding on frequency. For IBS specifically, the tight junction upregulation mechanism is relevant — gut barrier integrity is a real factor in IBS pathophysiology. Realistic expectation: stabilization over the medium term rather than acute symptom relief. If you want to address the respiratory side more specifically alongside, Bronchogen (AEDL) is the dedicated lung Cytogen — you could alternate one Bronchogen course and one Chonluten course annually if both angles matter to you.
CONTINUE IN THE APP
Open PepperLedger to ask the Coach about Chonluten and mucosal bioregulator protocols →
Free to join. The Coach understands the full Khavinson bioregulator system and can help you determine if Chonluten fits your protocol.
Free to join · No credit card · 23-day Pro trial included